GLP-1, GLP-2 & GLP-3 Research Guide: Incretin Biology, Gut Physiology & Metabolic Receptor Research

The glucagon-like peptides, GLP-1, GLP-2, and GLP-3, are a family of proglucagon-derived peptide hormones produced primarily in the intestinal L-cells and, in the case of GLP-1, also in the brainstem. These peptides play central roles in nutrient sensing, gastrointestinal regulation, glucose homeostasis, and metabolic signaling. With GLP-1 receptor agonists now among the most impactful drug classes in modern medicine (GLP-1S, liraglutide, GLP-2T), and GLP-2 analogs approved for short bowel syndrome, the GLP family represents one of the most actively researched areas in metabolic and gastrointestinal science. This guide reviews the structure, mechanisms, and research applications of GLP-1, GLP-2, and GLP-3 as research peptides. All content is for informational and scientific reference only.

Origins: Proglucagon Processing

All three glucagon-like peptides originate from the same precursor protein, proglucagon, encoded by the GCG gene. Tissue-specific post-translational processing of proglucagon by prohormone convertases (PC1/3 in intestinal L-cells and brainstem; PC2 in pancreatic alpha cells) yields different peptide profiles. In the pancreas, PC2 processing produces glucagon. In the intestine and brain, PC1/3 processing produces GLP-1, GLP-2, oxyntomodulin, and glicentin, a distinct set of biologically active peptides with dramatically different functions from glucagon.

GLP-1 (Glucagon-Like Peptide-1)

Structure and Endogenous Biology

GLP-1 is released from intestinal L-cells within minutes of nutrient ingestion, particularly in response to carbohydrates and fats. It is rapidly degraded by dipeptidyl peptidase-4 (DPP-4), with a plasma half-life of only 1–2 minutes for native GLP-1. Research peptide preparations of GLP-1 and its analogs allow study of GLP-1 receptor (GLP-1R) signaling without the rapid degradation limitation of endogenous GLP-1.

Mechanism: GLP-1 Receptor Signaling

GLP-1 binds GLP-1R, a class B GPCR expressed in pancreatic beta cells, intestine, brain, heart, kidney, and lung. GLP-1R activation signals primarily through Gαs → adenylyl cyclase → cAMP → PKA and Epac2, with downstream effects including:

• Glucose-dependent insulin secretion: GLP-1R activation potentiates glucose-stimulated insulin secretion (GSIS) from pancreatic beta cells, the “incretin effect.” This is the foundational mechanism of GLP-1-based diabetes drugs; crucially, the insulin-secretory effect is glucose-dependent (only active when blood glucose is elevated), conferring low hypoglycemia risk
• Glucagon suppression: GLP-1R on pancreatic alpha cells (and indirectly via somatostatin) suppresses glucagon secretion during the postprandial state, reducing hepatic glucose output
• Gastric emptying delay: GLP-1 slows gastric emptying, reducing the rate of nutrient absorption and postprandial glucose excursions
• Central satiety: GLP-1R in the hypothalamus and brainstem (area postrema, nucleus tractus solitarius) reduces appetite and food intake, the basis for weight loss effects of GLP-1 receptor agonists
• Beta cell preservation: Preclinical research shows GLP-1R activation promotes beta cell proliferation, reduces apoptosis, and may preserve beta cell mass in diabetes models
• Cardiovascular effects: GLP-1R is expressed on cardiomyocytes and vascular endothelium; GLP-1 improves myocardial function in ischemia models and reduces atherosclerotic plaque in preclinical studies, consistent with the cardiovascular benefits seen with GLP-1 agonist drugs in CVOTs

GLP-1 Research Applications

Research applications of GLP-1 peptide preparations span type 2 diabetes models, obesity research, beta cell biology, cardiovascular metabolism, and neuroprotection. The native peptide is used to study GLP-1R signaling mechanisms, receptor pharmacology, and incretin physiology without the confounds introduced by long-acting pharmaceutical analogs (GLP-1S, liraglutide).

GLP-2 (Glucagon-Like Peptide-2)

Structure and Endogenous Biology

GLP-2 is a 33-amino acid peptide co-secreted with GLP-1 from intestinal L-cells in response to nutrient intake. Unlike GLP-1, GLP-2 acts primarily on the gastrointestinal tract with minimal direct metabolic or glycemic effects. GLP-2 has a short half-life (~7 minutes) due to DPP-4 cleavage; the pharmaceutical analog teduglutide (Gattex®) is DPP-4-resistant and FDA-approved for short bowel syndrome (SBS).

Mechanism: GLP-2 Receptor Signaling

GLP-2 binds GLP-2R, a class B GPCR expressed primarily on enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons of the small and large intestine. GLP-2R signaling via cAMP/PKA produces:

• Intestinal epithelial proliferation: GLP-2 is the most potent known stimulus for intestinal crypt cell proliferation and villus growth, increasing mucosal surface area and absorptive capacity
• Reduction of intestinal permeability: GLP-2 strengthens tight junctions between enterocytes, reducing “leaky gut” and bacterial translocation, relevant to inflammatory bowel disease and critical illness research
• Nutrient absorption: By increasing villus height and upregulating nutrient transporters (SGLT1, GLUT2), GLP-2 enhances glucose, amino acid, and fat absorption
• Mesenteric blood flow: GLP-2 increases postprandial mesenteric blood flow, optimizing nutrient delivery to absorptive enterocytes
• Bone metabolism: GLP-2R is expressed on osteoclasts; GLP-2 inhibits bone resorption and has been studied in postprandial bone turnover regulation and osteoporosis research

GLP-2 Research Applications

GLP-2 research spans intestinal adaptation (short bowel syndrome models), inflammatory bowel disease, intestinal barrier function, gut microbiome interactions, and bone metabolism. The native peptide is used to study GLP-2R pharmacology, intestinal trophic signaling, and the physiological role of the postprandial GLP-2 response.

GLP-3 (Glucagon-Like Peptide-3 / Glicentin-Related Polypeptide)

Structure and Current Understanding

GLP-3 refers to the third glucagon-like sequence within proglucagon, though it is less characterized than GLP-1 and GLP-2 in the published literature. GLP-3 is structurally related to the glicentin-related polypeptide (GRPP) region of proglucagon and is produced as part of the intestinal proglucagon processing products. Its specific receptor has not been as definitively characterized as GLP-1R and GLP-2R, making it an active subject of investigation in receptor pharmacology and incretin biology research.

Research into GLP-3 is ongoing, with interest in potential roles in gastrointestinal motility, pancreatic function, and metabolic regulation that may complement or modulate GLP-1 and GLP-2 activity. As a research peptide, GLP-3 preparations are used to investigate proglucagon-derived peptide biology and potential novel receptor targets in the GLP family.

Comparative Overview: GLP-1, GLP-2, and GLP-3

The Incretin Effect and Combined GLP Research

The incretin effect, whereby oral glucose produces greater insulin secretion than intravenous glucose at identical blood glucose levels, is mediated primarily by GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This effect is substantially diminished in type 2 diabetes, making GLP-1 signaling a central mechanistic target in diabetes research. The simultaneous study of GLP-1 and GLP-2 together reflects the physiological reality that both are co-secreted from the same L-cells in response to the same nutritional stimuli, allowing researchers to study coordinated intestinal and metabolic responses to feeding.

Research and Storage Considerations

GLP peptide research preparations should be lyophilized to maximize stability during storage, with reconstitution in bacteriostatic water or sterile saline immediately prior to use. Storage at -20°C or below is standard for long-term preservation. As with all research peptides, HPLC purity ≥98% and mass spectrometry identity confirmation are essential quality parameters. Because GLP peptides are short-lived in biological systems due to DPP-4 degradation, experimental designs should account for the need for frequent administration or use of DPP-4 inhibitors in in vivo models to maintain active peptide levels.

Disclaimer

GLP-1, GLP-2, and GLP-3 research preparations are sold strictly for in vitro and preclinical research purposes. These are not approved drug products. GLP-1 and GLP-2 receptor agonist drugs exist for clinical use under physician supervision; the research peptides described here are distinct from pharmaceutical preparations. This content is for educational and scientific informational purposes only and does not constitute medical advice.

References

• Drucker DJ. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism, 27(4), 740–756.
• Brubaker PL, Drucker DJ. (2004). Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology, 145(6), 2653–2659.
• Jeppesen PB, et al. (2012). Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology, 143(6), 1473–1481.
• Nauck MA, Meier JJ. (2016). The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. The Lancet Diabetes & Endocrinology, 4(6), 525–536.
• Holst JJ. (2007). The physiology of glucagon-like peptide 1. Physiological Reviews, 87(4), 1409–1439.

Research-Grade Products Available

• GLP-2 T →
• GLP-1 S →
• GLP-3 R →